Last reviewed · How we verify

NCT04029883: BETA

Behavioral Economics to Improve Antihypertensive Therapy Adherence

Completed NA Results posted Last updated 19 September 2024
What this trial tests

NA trial testing Text Message in Hypertension in 60 participants. Completed in 31 July 2024.

Timeline
19 April 2022
Primary endpoint
1 February 2024
31 July 2024

Quick facts

Lead sponsorCedars-Sinai Medical Center
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposeother
Enrollment60
Start date19 April 2022
Primary completion1 February 2024
Estimated completion31 July 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Cedars-Sinai Medical Center

Who can join

18 and older, any sex, with Hypertension or Medication Adherence. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Electronically Measured Mean Medication Adherence During Intervention Primary · 3 months

The MEMS-data collected continuously over the course of the three-month intervention period will be used to calculate the primary adherence variable, which is defined as the percentage of timely (within 1 hour of anchor time) actual bottle openings out of the total number of prescribed bottle openings (# of actual once-a-day bottle openings within 1 hour of anchor time during the intervention period / # of prescribed once-a-day bottle openings during the intervention period). Only one of the anti-hypertension (AH) medications will be used to measure adherence

GroupValue95% CI
Control Group87± 22
Message Group95± 34
Incentive Group92± 38

Sponsor's own description

Hypertension represents a major cardiovascular risk factor that can be controlled through the use of medications, yet medication non-adherence represents a common problem that leaves patients at elevated risk for adverse cardiovascular outcomes. Interventions to improve medication adherence have thus far been either unsuccessful or unsustainable. The investigators propose an intervention that leverages insights from behavioral economics to improve medication adherence among hypertensive patients. Strong data indicates that linking the taking of medications to daily routines ('anchoring') increases adherence, however, existing interventions built on this information have failed to create successful, long term improvements in medication adherence. This study aims to leverage behavioral economic insights to improve medication adherence to antihypertensive medications.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Barriers and facilitators of habit building for long-term adherence to antihypertensive therapy among people with hypertensive disorders in Los Angeles, California: a qualitative study.
    Ghai I, Ghai I, Palimaru A, Ebinger JE, et al · · 2024 · cited 2× · PMID 38991671 · DOI 10.1136/bmjopen-2023-079401
  2. Behavioural Economics to Improve Antihypertensive Therapy Adherence (BETA): protocol for a pilot randomised controlled trial in Los Angeles.
    Ebinger JE, Ghai I, Ghai I, Barajas D, et al · · 2023 · cited 2× · PMID 36697048 · DOI 10.1136/bmjopen-2022-066101
  3. Impact of behavioral economics to improve antihypertensive therapy adherence, a pilot randomized controlled trial in Los Angeles.
    Linnemayr S, Ghai I, Palimaru A, Barajas D, et al · · 2025 · PMID 41188444 · DOI 10.1038/s41598-025-94805-5

Verify or expand the search:

Other trials of Text Message

Trials testing the same drug.

Other recruiting trials for Hypertension

Currently open trials in the same condition.

Other Cedars-Sinai Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04029883.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing